Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TITAN PHARMACEUTICAL (TTP) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (307)	10/21/2005 12:58:51 PM
From: tom pope	Read Replies (1) \| Respond to of 362

Here's an angle I'd never considered - from the YMB (not that I think it deserving of much consideration). insider buying nothing more then an insurance policy from getting sued

To: Icebrg who wrote (307)	10/26/2005 6:34:52 PM
From: Icebrg	Read Replies (2) \| Respond to of 362

Now a director has been buying some shares from the market. Hubert Huckel bought 25.700 shares at prices around 1,70. After these transactions he holds 62.200 shares. Erik Hubert Huckel, M.D. – Executive committee; Audit committee and Compensation committee. Dr. Huckel served as Chairman of the Board of Hoechst-Roussel Pharmaceuticals, Inc., Chairman and President of Hoechst-Roussel Agri-Vet Company, and a member of the Executive Committee of Hoechst Celanese Corporation until his retirement in December 1992. Dr. Huckel currently serves on the Board of Directors of Thermogenesis, Corp. and Gynetics, Inc. He has been a director of Titan Pharmceuticals since October 1995.